CoChat

Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders

Open access
Kelesidis, Theodoros, Pothoulakis, Charalabos · 2012 · Therapeutic Advances in Gastroenterology

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Abstract

Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. This review discusses the evidence for efficacy and safety of S. boulardii as a probiotic for the prevention and therapy of gastrointestinal disorders in humans.

Overview

Integrity signals

Registry

Crossref · 10.1177/1756283x11428502

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 130 references

Research works printed but not linked: 10

  1. Bennani A. (1990) Randomised trial of Saccharomyces boulardii in the treatment of functional colon disorders. L’Objectif Medical 73: 56–61.
  2. 10.1097/00005176-199305000-00013 · doi:10.1097/00005176-199305000-00013 · Paper page
  3. Castaneda C., Garcia E., Santa Cruz M., Fernandez M., Monterrey P. (1995) Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Rev Mex Pueric Pediatr 2: 12–16.
  4. Elmer G.W., Moyer K.A., Vega R., Surawicz C.M., Collier A.C., Hooton T.M., et al. (1995) Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microb Ther 25: 23–31.
  5. 10.1046/j.1439-0507.1999.00449.x · DOI · Paper page
  6. 10.1111/j.1651-2227.2005.tb01848.x · doi:10.1111/j.1651-2227.2005.tb01848.x · Paper page
  7. Hochter W., Chase D., Hagenhoff G. (1990) Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wschr 132: 188–192.
  8. Kollaritsch H., Kremsner P., Wiedermann G., Scheiner O. (1989) Prevention of traveller’s diarrhea: comparison of different non-antibiotic preparations. Travel Med Internat 7: 9–18.
  9. Maupas J.L., Champemont P., Delforge M. (1983) Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebo-controlled study. Med Chir Dig 12: 77–79.
  10. Schwenzer V.B. (1998) Saccharomyces boulardii. Deutsche Apotheker Zeitung 138: 75–77.

Cited by

See all 378

Metadata

Authors
Kelesidis, T., & Pothoulakis, C.
Affiliations
University of California, Los Angeles (US)
Venue
Therapeutic Advances in Gastroenterology
Published
2011-11-11
Volume
5
Issue
2
Pages
111-125
ISSN
  • 1756-283X (ISSN-L)
  • 1756-2848
OpenAlex
W2008639012
Cited by
377
References
131
Citations by year
2026: 44 · 2025: 44 · 2024: 40 · 2023: 26 · 2022: 45 · 2021: 42 · 2020: 21 · 2019: 20 · 2018: 19 · 2017: 24 · 2016: 14 · 2015: 19 · 2014: 11 · 2013: 6 · 2012: 2
FWCI
8.88
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Gastroenterology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR000124)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
Saccharomyces boulardii, probiotics, gastrointestinal diseases, biologic therapy, gut microbiota, mechanism of action, efficacy, safety, adverse events

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. https://app.cochat.ai/papers/10.1177/1756283x11428502
The paper
Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x11428502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.